IS7357A - Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun - Google Patents

Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun

Info

Publication number: IS7357A
Authority: IS; Iceland
Prior art keywords: benzothiazepine; bile acid; acid transport; reduce cholesterol; cholesterol elevation
Prior art date: 2002-01-26

Application number

IS7357A

Other languages

English (en)

Inventor

Lindqvist Ann-Margret

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-26

Filing date

2004-07-21

Publication date

2004-07-21

2004-07-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-07-21 Publication of IS7357A publication Critical patent/IS7357A/is

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
239000003613 bile acid Substances 0.000 title 1
235000012000 cholesterol Nutrition 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS7357A 2002-01-26 2004-07-21 Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun IS7357A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0201850.5A GB0201850D0 (en)	2002-01-26	2002-01-26	Therapeutic treatment
PCT/GB2003/000350 WO2003061663A1 (en)	2002-01-26	2003-01-23	Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia

Publications (1)

Publication Number	Publication Date
IS7357A true IS7357A (is)	2004-07-21

Family

ID=9929835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7357A IS7357A (is)	2002-01-26	2004-07-21	Notkun bensóþíasepíns með tálmvirkni gegn flutningi gallsýru í dausgörn til að draga úr kólesterólhækkun

Country Status (17)

Country	Link
US (1)	US20050124557A1 (is)
EP (1)	EP1478368A1 (is)
JP (1)	JP2005523255A (is)
KR (1)	KR20040079949A (is)
CN (1)	CN1617729A (is)
BR (1)	BR0307093A (is)
CA (1)	CA2473721A1 (is)
GB (1)	GB0201850D0 (is)
HU (1)	HUP0500009A3 (is)
IS (1)	IS7357A (is)
MX (1)	MXPA04007201A (is)
NO (1)	NO20043549L (is)
PL (1)	PL371521A1 (is)
RU (1)	RU2004126148A (is)
TW (1)	TW200302089A (is)
WO (1)	WO2003061663A1 (is)
ZA (1)	ZA200405866B (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en)	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en) *	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
RS20050532A (sr)	2003-01-14	2007-12-31	Arena Pharmaceuticals Inc.,	Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en) *	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
KR20060056944A (ko)	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
EP2367554A4 (en) *	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP4137137A1 (en)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
MX366925B (es) *	2010-11-04	2019-07-31	Albireo Ab	Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en)	2010-11-08	2013-09-12	Albireo Ab	Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
MY176863A (en) *	2010-11-08	2020-08-24	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
US20120114588A1 (en) *	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EA038594B1 (ru)	2011-10-28	2021-09-21	Шайр Хьюман Дженетик Терапис, Инк.	Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en)	2014-06-25	2015-12-30	Ea Pharma Co., Ltd.	Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CA3011595C (en)	2016-02-09	2024-01-02	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh)	2016-02-09	2022-01-04	阿尔比里奥公司	口服考来烯胺制剂及其用途
JP6954927B2 (ja)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
JP7328207B2 (ja)	2017-08-09	2023-08-16	アルビレオ・アクチボラグ	コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CN111032019B (zh)	2017-08-09	2022-07-05	阿尔比里奥公司	考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja)	2018-06-05	2023-12-04	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
KR20210024033A (ko)	2018-06-20	2021-03-04	알비레오 에이비	오데빅시바트의 약학 제제
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
SG11202108566VA (en)	2019-02-06	2021-09-29	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh)	2019-02-06	2024-07-23	阿尔比里奥公司	苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
JP7665621B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110885A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158195A1 (en)	2019-12-04	2021-06-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en)	2020-08-03	2025-03-07	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt)	2020-12-04	2023-10-03	Albireo Ab	Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh)	2021-06-03	2024-01-16	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN119053330A (zh)	2022-04-22	2024-11-29	阿尔比里奥公司	皮下给药asbt抑制剂
EP4536232A1 (en)	2022-06-09	2025-04-16	Albireo AB	Treating hepatitis
CN119487013A (zh)	2022-07-05	2025-02-18	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4629997A1 (en)	2022-12-09	2025-10-15	Albireo AB	Asbt inhibitors in the treatment of renal diseases
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900757A (en) *	1988-12-08	1990-02-13	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
ATE242258T1 (de) *	1997-03-14	2003-06-15	Aventis Pharma Gmbh	Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
SE0000772D0 (sv) *	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
EG26979A (en) *	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds

2002
- 2002-01-26 GB GBGB0201850.5A patent/GB0201850D0/en not_active Ceased
2003
- 2003-01-23 CN CNA038023547A patent/CN1617729A/zh active Pending
- 2003-01-23 MX MXPA04007201A patent/MXPA04007201A/es not_active Application Discontinuation
- 2003-01-23 RU RU2004126148/14A patent/RU2004126148A/ru not_active Application Discontinuation
- 2003-01-23 EP EP03731763A patent/EP1478368A1/en not_active Withdrawn
- 2003-01-23 PL PL03371521A patent/PL371521A1/xx not_active Application Discontinuation
- 2003-01-23 CA CA002473721A patent/CA2473721A1/en not_active Abandoned
- 2003-01-23 US US10/502,355 patent/US20050124557A1/en not_active Abandoned
- 2003-01-23 BR BR0307093-0A patent/BR0307093A/pt not_active Application Discontinuation
- 2003-01-23 HU HU0500009A patent/HUP0500009A3/hu unknown
- 2003-01-23 JP JP2003561607A patent/JP2005523255A/ja active Pending
- 2003-01-23 WO PCT/GB2003/000350 patent/WO2003061663A1/en not_active Ceased
- 2003-01-23 KR KR10-2004-7011445A patent/KR20040079949A/ko not_active Withdrawn
- 2003-01-24 TW TW092101585A patent/TW200302089A/zh unknown
2004
- 2004-07-21 IS IS7357A patent/IS7357A/is unknown
- 2004-07-22 ZA ZA200405866A patent/ZA200405866B/en unknown
- 2004-08-25 NO NO20043549A patent/NO20043549L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0500009A3 (en)	2006-05-29
PL371521A1 (en)	2005-06-27
CA2473721A1 (en)	2003-07-31
GB0201850D0 (en)	2002-03-13
WO2003061663A1 (en)	2003-07-31
EP1478368A1 (en)	2004-11-24
TW200302089A (en)	2003-08-01
RU2004126148A (ru)	2005-05-27
NO20043549L (no)	2004-08-25
CN1617729A (zh)	2005-05-18
JP2005523255A (ja)	2005-08-04
ZA200405866B (en)	2006-07-26
BR0307093A (pt)	2004-12-28
MXPA04007201A (es)	2004-11-26
KR20040079949A (ko)	2004-09-16
US20050124557A1 (en)	2005-06-09
HUP0500009A2 (hu)	2005-04-28

Publication	Publication Date	Title
LTC1761540I2 (lt)	2019-04-10	Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1567112T3 (da)	2009-02-09	Thiazolidin-4-oner til at hæmme hYAK3-proteiner
PL1636190T3 (pl)	2012-10-31	Trwały kryształ związku 4-oksochinoliny
ATE535586T1 (de)	2011-12-15	Zusätze zu wasserfesten gipsprodukten
FI20022129A7 (fi)	2004-02-06	Rasvahappokoostumus, sen valmistus ja käyttö
DE60307556D1 (de)	2006-09-28	Verbindungsstruktur von Verbindern
EP1765761A4 (en)	2010-05-19	NOVEL ANALOGUES OF 3-O-ACETYL-11-KETO-BETA-BOSWELLIC ACID
PL1741318T3 (pl)	2017-08-31	Wykorzystanie elektrod lampy jako anteny
DE60327253D1 (de)	2009-05-28	Nahrungszusammensetzung enthaltend l(+)-milchsäure
FI20021531A0 (fi)	2002-08-28	Muurausmenetelmä
IS7488A (is)	2004-10-04	Dreyfasamsetning í föstu formi
FR2908045B1 (fr)	2009-01-09	Utilisation anti-pelliculaire d'un principe actif riche en tannis hydrolysables
ATA14002004A (de)	2005-11-15	Pumpfähiger selbstnivellierender magnesiaestrich
PT1781145T (pt)	2018-11-29	Ferramenta para facilitar o consumo de substâncias ingeríveis
ZA200701800B (en)	2008-09-25	Use of thyroid hormone conversion inhibitors
PL381612A1 (pl)	2007-06-11	Pirydynowe pochodne alkilooksindoli jako aktywne czynniki 5-HT7
DE602006020024D1 (de)	2011-03-24	Rückgewinnung von schwefelsäure
ITMI20040218A1 (it)	2004-05-10	Uso di neridronato sodico per promuovere la neoformazione ossea
TW552891U (en)	2003-09-11	Improved structure of closet easy to assemble
SE0601411L (sv)	2006-06-28	Förfarande vid beredning
EE04848B1 (et)	2007-06-15	Meetod (-)-R-homosidrunhappe- ja (+)-S-homosidrunhappe laktoonide saamiseks
DK1706417T3 (da)	2008-09-29	Anvendelse pollenisolerede proteiner til inhibering af anthraxtoxinaktivitet
NO20021905D0 (no)	2002-04-23	Plaster med salveblemme
FI20115121L (fi)	2011-02-09	Rasvahappokoostumuksen valmistus
TW560715U (en)	2003-11-01	Improved structure of CPU socket